文献速递临床试验与 GCP流行病学与生物统计

抗疟药青蒿琥酯-甲氟喹与吡喹酮治疗非洲儿童血吸虫病的开放标签随机对照试验

Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial.
PubMed 文献 · Nat Med · 2024-01-04

在塞内加尔北部六个血吸虫病流行村庄的小学中,726名6-14岁儿童按1:1随机接受吡喹酮单剂40 mg/kg(n=364)或青蒿琥酯-甲氟喹三日方案(青蒿琥酯4 mg/kg联合甲氟喹8 mg/kg每日,n=362)。治疗后4周治愈率青蒿琥酯-甲氟喹组为59.6%(208/349),吡喹酮组为62.1%(211/340),差值-2.5%(95%CI -9.8至4.8),满足预设非劣效界值10%。药物相关不良事件均为轻中度,青蒿琥酯-甲氟喹组28/361(7.8%;95%CI 5.4-11.0)高于吡喹酮组8/363(2.2%;95%CI 1.1-4.3),P<0.001。

要点

  • 青蒿琥酯-甲氟喹按抗疟剂量给药对血吸虫病非劣效于标准治疗吡喹酮,差值-2.5%(95%CI -9.8至4.8),非劣效界值10%。
  • 药物相关不良事件均为轻中度,青蒿琥酯-甲氟喹组7.8%(28/361)高于吡喹酮组2.2%(8/363),P<0.001。
  • 作者认为需在不同人群和流行病学环境开展多中心试验以证实这些发现。

核心结论

  • 青蒿琥酯-甲氟喹按抗疟剂量给药对以埃及血吸虫为主的血吸虫病治疗中等安全且非劣效于标准治疗吡喹酮。

研究设计与样本

  • 概念验证、实用性、开放标签、随机对照试验,在塞内加尔北部六个血吸虫病流行村庄的小学开展。
  • 726名6-14岁儿童按1:1随机分为吡喹酮组(标准治疗:40 mg/kg单剂;n=364)和青蒿琥酯-甲氟喹组(抗疟剂量:青蒿琥酯4 mg/kg联合甲氟喹8 mg/kg每日连续三天;n=362)。
  • 纳入标准为尿液和/或粪便镜检检出血吸虫虫卵;8名不符合纳入标准者被排除出疗效分析,剩余718名参与者中位年龄9岁,男性399名(55.6%),女性319名(44.4%)。
  • 99.3%感染埃及血吸虫(Schistosoma haematobium),15.2%感染曼氏血吸虫(S. mansoni)。
  • 主要结局为治疗后4周镜检评估的治愈率及青蒿琥酯-甲氟喹与吡喹酮药物相关不良事件频率。

主要发现

  • 治愈率青蒿琥酯-甲氟喹组为59.6%(208/349),吡喹酮组为62.1%(211/340),差值-2.5%(95%CI -9.8至4.8),满足预设非劣效界值10%。
  • 药物相关不良事件均为轻中度,青蒿琥酯-甲氟喹组报告28/361(7.8%;95%CI 5.4-11.0),吡喹酮组报告8/363(2.2%;95%CI 1.1-4.3),P<0.001。

关键数值与推荐

  • 非劣效界值预设为10%,实际治愈率差值-2.5%(95%CI -9.8至4.8)满足非劣效标准。
  • 吡喹酮标准治疗剂量为40 mg/kg单剂;青蒿琥酯-甲氟喹抗疟剂量为青蒿琥酯4 mg/kg联合甲氟喹8 mg/kg每日连续三天。

临床怎么用

  • 作者认为青蒿琥酯-甲氟喹按抗疟剂量给药对血吸虫病治疗中等安全且非劣效于标准治疗吡喹酮。
  • 作者指出需在不同人群和流行病学环境开展多中心试验以证实这些发现。

局限性

  • 作者指出需在不同人群和流行病学环境开展多中心试验以证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schistosomiasis treatment entirely relies on a single drug, praziquantel, prompting research into alternative therapeutics. Here we evaluated the efficacy and safety of the antimalarial combination artesunate-mefloquine for the treatment of schistosomiasis in a proof-of-concept, pragmatic, open-label, randomized controlled trial in primary schools of six villages endemic for schistosomiasis in northern Senegal. Children (6-14 years) were eligible if Schistosoma eggs were detected by microscopy in urine and/or stool. In total, 726 children were randomized 1:1 to praziquantel (standard care: 40 mg kg-1 single dose; n = 364) or to artesunate-mefloquine (antimalarial dosage: artesunate 4 mg kg-1 and mefloquine 8 mg kg-1 daily for three consecutive days; n = 362). Eight children not meeting the inclusion criteria were excluded from efficacy analysis. Median age of the remaining 718 participants was 9 years; 399 (55.6%) were male, and 319 (44.4%) female; 99.3% were infected with Schistosoma haematobium and 15.2% with S. mansoni. Primary outcomes were cure rate, assessed by microscopy, and frequency of drug-related adverse effects of artesunate-mefloquine versus praziquantel at 4 weeks after treatment. Cure rate was 59.6% (208/349) in the artesunate-mefloquine arm versus 62.1% (211/340) in the praziquantel arm. The difference of -2.5% (95% confidence interval (CI) -9.8 to 4.8) met the predefined criteria of noninferiority (margin set at 10%). All drug-related adverse events were mild or moderate, and reported in 28/361 children receiving artesunate-mefloquine (7.8%; 95% CI 5.4 to 11.0) versus 8/363 (2.2%; 95% CI 1.1 to 4.3) receiving praziquantel (P < 0.001). Artesunate-mefloquine at antimalarial dosage was moderately safe and noninferior to standard-care praziquantel for the treatment of schistosomiasis, predominantly due to S. haematobium. Multicentric trials in different populations and epidemiological settings are needed to confirm these findings. ClinicalTrials.gov identifier: NCT03893097 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Bottieau E, Mbow M, Brosius I, et al. Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial. Nat Med. 2024. PMID: 38177851. doi:10.1038/s41591-023-02719-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。